Mechanism of Action
After ingestion, rutin crosses the stomach and small intestine without significant degradation. In the colon, bacterial glycosidases cleave the sugar-quercetin bond, releasing the active aglycone.
Absorbed quercetin circulates as conjugated metabolites. These metabolites neutralise free radicals (unstable molecules that damage cell membranes and DNA) by donating an electron. They also support endothelial function (the cellular layer lining blood vessels) by promoting nitric oxide production, a molecule that regulates vascular flexibility.
Before complete hydrolysis, intact rutin interacts directly with intestinal mucosal cells. It modulates the local production of mediators involved in the inflammatory response. This dual site of action (intestinal and systemic) defines the biological profile of this flavonoid.
Key Benefits
- Strong
Meta-analyses of quercetin supplementation (of which rutin is a sustained-release source) report a significant reduction in systolic blood pressure in subjects with elevated values.
- Moderate
Clinical trials on rutosides demonstrate improved capillary resistance, reduced excessive vascular permeability and decreased lower limb oedema in subjects with venous fragility.
- Moderate
Quercetin supplementation (as rutin or aglycone) is associated with improved blood lipid parameters in several controlled trials, including reduced oxidised LDL cholesterol.
- Emerging
Quercetin, the aglycone progressively released by rutin, is the subject of human clinical trials targeting senescent cells (dysfunctional cells that accumulate with age).
- Emerging
Preliminary human data suggest a favourable effect of rutin supplementation on glycaemic metabolism markers, including fasting blood glucose.
Dosage & Forms
Clinical literature uses rutin doses ranging from 250 mg to 1,000 mg per day. Trials on vascular function typically employ 500 mg/day.
Several forms of quercetin exist in supplementation: free aglycone, isoquercetin (a rapidly absorbed monoglucoside), and rutin (a diglycoside with colonic release). The aglycone offers a high but brief plasma peak, with significant gastric degradation. Isoquercetin shows the highest absolute bioavailability. Rutin is characterised by a prolonged exposure profile to active metabolites, suited to once-daily dosing.
In the Singular Formula
Inclusion rationale
Glycoside flavonoid of the flavonol family, rutin is one of the most widespread polyphenols in the plant kingdom. Naturally abundant in buckwheat, citrus fruits, capers and green tea, it takes its name from rue (Ruta graveolens), the plant in which it was first identified. Rutin stands out among flavonoids for its rutinoside group (glucose-rhamnose disaccharide), which gives it superior water solubility and specific absorption kinetics. In the intestine, bacterial glycosidases progressively release quercetin (the active aglycone), ensuring sustained release into the circulation rather than a brief plasma peak. This sustained-release mechanism represents a concrete pharmacokinetic advantage over free quercetin, which is rapidly metabolized. Rutin has a long history of use in European phytotherapy for its affinity with the vascular wall. It contributes to the maintenance of normal capillary permeability and blood vessel resistance, two parameters whose progressive deterioration accompanies vascular aging.
Selected form
Rutin extracted from Sophora japonica flowers (pagoda tree), using ethanol-water extraction with an approximate 7:1 ratio. Rutin is a flavonoid glycoside: it combines quercetin, a flavonol, with a disaccharide (rutinose). This natural glycosylation improves quercetin's solubility and stability in the digestive environment. Unlike free quercetin, rutin withstands gastric degradation and is progressively hydrolysed in the intestine. Historically designated 'vitamin P' for its properties related to vascular permeability. Quality: vegan, non-GMO, pesticide-free, no excipient, preservative-free, Halal and Kosher certified.
Formula dosage
0 to 500 mg.
Synergies in the formula
Linked Biomarkers
Safety & Precautions
Rutin has a long history of safe use. Rutosides have been used in European phytotherapy for several decades. At common doses (250 to 1,000 mg/day), no serious adverse effects have been reported in published clinical trials.
Mild digestive disturbances (nausea, abdominal discomfort) are possible at high doses. Rutin is not recommended during pregnancy and breastfeeding due to insufficient data. Individuals taking anticoagulants or antiplatelet agents should consult a healthcare professional before supplementation, as quercetin may modulate platelet aggregation in vitro.
No significant dietary interactions have been documented. Rutin is naturally present in many common foods (buckwheat, citrus fruits, capers, green tea), reflecting its compatibility with human metabolism.
Scientific Studies
| Authors | Year | Type | Journal | |
|---|---|---|---|---|
| Ganeshpurkar A, Saluja AK | 2017 | Systematic Review | Saudi Pharmaceutical Journal | View on PubMed |
The Pharmacological Potential of Rutin Comprehensive review of rutin pharmacological properties, covering its effects on vascular function, glucose metabolism and cellular protection in human and preclinical models. | ||||
| Erlund I et al. | 2000 | Randomised Controlled Trial | European Journal of Clinical Pharmacology | View on PubMed |
Pharmacokinetics of quercetin from quercetin aglycone and rutin in healthy volunteers Pharmacokinetic study comparing quercetin absorption from free aglycone and rutin in healthy volunteers, demonstrating distinct plasma exposure profiles. | ||||
| Serban MC et al. | 2016 | Meta-analysis | Journal of the American Heart Association | View on PubMed |
Effects of Quercetin on Blood Pressure: A Systematic Review and Meta-Analysis of Randomized Controlled Trials Meta-analysis of seven randomised controlled trials showing a significant reduction in systolic and diastolic blood pressure with quercetin supplementation. | ||||
| Hickson LJ et al. | 2019 | Randomised Controlled Trial | EBioMedicine | View on PubMed |
Senolytics decrease senescent cells in humans: Preliminary report from a clinical trial of Dasatinib plus Quercetin in individuals with diabetic kidney disease First human clinical trial demonstrating that the dasatinib plus quercetin protocol reduces senescent cell burden, with measurable effects eleven days after a three-day administration. | ||||
| Chua LS | 2013 | Systematic Review | Journal of Ethnopharmacology | View on PubMed |
A review on plant-based rutin extraction methods and its pharmacological activities Review of plant-based rutin extraction methods and documented pharmacological activities, including effects on vascular function and metabolism. | ||||